ERBB2 TMD/JMD heterodimers trans-autophosphorylate

Stable Identifier
R-HSA-9665709
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

Phosphorylation of tyrosine residues in the C-tail of ERBB2 was shown for the following ERBB2 TMD/JMD mutants:
ERBB2 V659E (Pahuja et al. 2018);
ERBB2 V659K (Pahuja et al. 2018);
ERBB2 G660D (Pahuja et al. 2018);
ERBB2 G660R (Pahuja et al. 2018);
ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1248 demonstrated);
ERBB2 R677L (Pahuja et al. 2018);
ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1248 demonstrated; Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018)

Phosphorylation of tyrosine residues in the C-tail of EGFR was demonstrated for ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1068) and ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1068).

Phosphorylation of tyrosine residues in the C-tail of ERBB3 was demonstrated for ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1197) and ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1197).

Signaling by ERBB2 V659K, ERBB2 G660D, ERBB2 G660R, ERBB2 R677L, ERBB2 E693K and ERBB2 Q709L has not been sufficiently studied and they are annotated as candidates.

Literature References
PubMed ID Title Journal Year
30449325 Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations

Pahuja, KB, Nguyen, TT, Jaiswal, BS, Prabhash, K, Thaker, TM, Senger, K, Chaudhuri, S, Kljavin, NM, Antony, A, Phalke, S, Kumar, P, Mravic, M, Stawiski, EW, Vargas, D, Durinck, S, Gupta, R, Khanna-Gupta, A, Trabucco, SE, Sokol, ES, Hartmaier, RJ, Singh, A, Chougule, A, Trivedi, V, Dutt, A, Patil, V, Joshi, A, Noronha, V, Ziai, J, Banavali, SD, Ramprasad, V, DeGrado, WF, Bueno, R, Jura, N, Seshagiri, S

Cancer Cell 2018
24971884 Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib

de Martino, M, Zhuang, D, Klatte, T, Rieken, M, RouprĂȘt, M, Xylinas, E, Clozel, T, Krzywinski, M, Elemento, O, Shariat, SF

Cancer Biol. Ther. 2014
23220880 Activating HER2 mutations in HER2 gene amplification negative breast cancer

Bose, R, Kavuri, SM, Searleman, AC, Shen, W, Shen, D, Koboldt, DC, Monsey, J, Goel, N, Aronson, AB, Li, S, Ma, CX, Ding, L, Mardis, ER, Ellis, MJ

Cancer Discov 2013
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
protein tyrosine kinase activity of ERBB2 TMD/JMD mutants:Ligand-Activated EGFR,ERBB3,(ERBB4) [plasma membrane]
Physical Entity
Activity
Normal reaction
Disease
Name Identifier Synonyms
cancer 162 malignant tumor, malignant neoplasm, primary cancer
Authored
Reviewed
Created
Cite Us!